ReviewDrug design, development and therapy2025
The Effects of Obesity on Lung Physiology, the Prevalence and Severity of Chronic Pulmonary Diseases, and Inhalation Treatment.
Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Obesity in Chronic Obstructive Pulmonary Disease (COPD): Effects on Inflammation, Immune System, Susceptibility to Viral Infections, and Mortality.Pathogens (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity itself induces macroscopic, microscopic, and functional changes in the lungs, potentially making obese individuals more susceptible to acute and chronic pulmonary diseases. Apart from direct contribution to the course of the disease, obesity-induced alterations of the respiratory tract may influence the delivery and efficacy of inhaled formulations. The review examined obesity-induced changes in healthy lungs and the link between obesity and the prevalence and severity of chronic respiratory diseases. Fat accumulation at the tissue and cellular levels, as well as an increased thickness of the smooth muscle layer and an increase in the extracellular matrix, caused a reduction in lung compliance, resistance, reactance, and lung volumes. Conversely, airway hyperreactivity and closure increased, and ventilation/perfusion mismatch was observed. Changes in deposition, metabolization, and permeation across the respiratory barrier in obese lungs may alter the availability of inhaled drugs. Obesity-induced lung alterations may in part explain the higher reported doses of the bronchodilators and anticholinergics in obese compared to normal-weight asthma patients. Based on the observed changes, formulations with smaller particle sizes that require lower airflow may be more effective for obese patients with obstructive lung diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.